Influence of metabolic syndrome on development of cardiac allograft vasculopathy in the transplanted heart

Transplantation

Volumn 93, Issue 1, 2012, Pages 106-111

  Sánchez Gómez, Juan Miguel ^a,b   Martínez Dolz, Luis ^a   Sánchez Lázaro, Ignacio ^a   Almenar, Luis ^a   Sánchez Lacuesta, Elena ^a   Muñoz Giner, Begoña ^a   Portolés, Manuel ^a   Rivera, Miguel ^a   Valera Román, Alfonso ^c   González Juanatey, Jose Ramón ^c   Tejada Ponce, David ^a   Agüero, Jaime ^a   Buendía, Francisco ^a   Salvador, Antonio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Cardiac allograft vasculopathy; Intravascular ultrasound; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE FACTORS; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 84655175016     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182398058     Document Type: Article

References (36)

1. Almenar L, Segovia J, Crespo-Leiro MG, et al. Spanish Heart Transplantation Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984 -2009). Rev Esp Cardiol 2010; 63: 1317
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415.
3. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433.
4. Ford, ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with metabolic syndrome: A summary of the evidence. Diabetes Care 2005; 28: 1769.
5. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006; 119: 812.
6. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403.
7. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113.
8. Raichlin ER, McConnell JP, Lerman A, et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 2007; 26: 826.
9. Valantine H, Rickenbacker P, Kemna M, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: A prospective study. Circulation 2001; 103: 2144.
10. Schmauss D, Weis M. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 2131.
11. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter restrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplants recipients. J Heart Lung Transplant 2006; 25: 1063.
12. Sánchez-Lázaro IJ, Almenar Bonet L, Moro Ló pez J, et al. Influence of traditional cardiovascular risks factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation. Transplant Proc 2008; 40: 3056.
13. Sharples LD, Jackson CH, Parameshwar J, et al. Diagnostic accuracy of coronary angiography and risks factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation 2003; 76: 679.
14. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 2004; 43: 1034.
15. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004; 109: 500.
16. Fateh-Moghadam S, Bocksch W, Wesely R, et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003; 76: 1470.
17. Nagji AS, Hranjec T, Swenson BR, et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: Implications for donor allocation. Ann Thorac Surg 2010; 90: 168.
18. Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 1180.
19. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentyseventh official adult heart transplant report-2010. J Heart Lung Transplant 2010; 29: 1089.
20. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. JAmColl Cardiol 2005; 45: 1538.
21. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532.
22. Kapadia S, Nissen S, Ziada K, et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study. J Am Coll Cardiol 2001; 38: 206.
23. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356.
25. Grundy SM. Metabolic syndrome pandemic. Arteroscler Thromb Vasc Biol 2008; 28: 629.
26. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipents: Prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109.
27. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
28. Ozdemir FN, Karakan S, Akgul A, et al. Metabolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009; 41: 2808.
29. Cordero Fort A, Gavira JJ, Alegría-Barrero E, et al. Prevalence de metabolic syndrome in heart transplants patients: Role of previous cardiopathy and years since the procedure-the TRACA study. J Heart Lung Transplant 2006; 25: 1192.
30. Mancia G, De Backer G, Dominiczak A, et al. ESH/ESC 2007 Guidelines for the Management of Arterial Hypertension. Rev Esp Cardiol 2007; 60: 968.e1.
31. Potena L, Valantine HA. Cardiac allograft vasculopathy and insulin resistance-Hope for new therapeutic targets. Endocrinol Metab Clin North Am 2007; 36: 965.
32. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735.
33. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diaebet Med 1998; 15: 539.
34. Meigs J. Metabolic syndrome and the risk for type 2 diabetes. Expert Rev Endocrin Metab 2006; 1: 57.
35. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter restrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplants recipients. J Heart Lung Transplant 2006; 25: 1063.
36. Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3445.